XPH News and Press, SPDR S&P Pharmaceuticals From 01/06/24

2024-01-06 08:15:00 ET Summary Global equity markets experienced a surge in 2023 driven by economic growth and investor confidence. US equity returns exceeded expectations despite concerns about higher rates, inflation, and geopolitical tension. In 2024, investors should focus...

2024-01-06 05:10:52 ET Summary Pfizer has generally paid high prices for M&A, above industry norms (20x vs 10x EV/Revenue deal multiples). Oncology has been a lagging business for Pfizer despite being a hot growth area (1.5% 3-yr CAGR for Oncology vs 4.5% 3-yr CAGR for non-COV...

2023-12-21 08:25:00 ET Summary Given strong recent market returns and another wave of capital inflows, the backdrop is probably not enough to lead to strong tactical performance from risk assets. The US has a more favorable demographic trend; its working-age population is expected...

2023-12-20 06:19:00 ET Summary Can the Magnificent 7 continue to rally into 2024? How the Magnificent 7's rise compares to the dot-com bubble. Why the rise in tech stocks highlights shortcomings for the markets. The rise of the Magnificent 7 tech stocks has been a ke...

2023-12-18 12:09:20 ET More on SPDR S&P Pharmaceuticals ETF Seeking Alpha’s Quant Rating on SPDR S&P Pharmaceuticals ETF Dividend scorecard for SPDR S&P Pharmaceuticals ETF For further details see: SPDR S&P Pharmaceuticals ETF declares quar...

2023-12-09 03:00:00 ET Summary The global markets experienced high volatility in 2023 due to factors such as high interest rates, bank failures, and a surge in bond yields. The macro environment in 2024 is expected to be complex and interesting, with rewards for investors who are ...

2023-12-08 04:54:49 ET More on Pfizer, Astellas Pharma Johnson & Johnson Vs. Pfizer: Better Pharma Stock? Pfizer: This Year's Disaster Should Set The Stage For A Strong 2024 Pfizer: Slimming Down After COVID Franchise And Obesity Pipeline Setbacks Astella...

2023-11-22 02:15:00 ET Summary Q3 earnings season had many familiar refrains relative to the year’s first two quarters. One difference was a return to positive earnings growth for the first time since Q3 2022. Not unlike the first two quarters of the year, earnings for ...

2023-11-21 09:05:00 ET Summary A more volatile macroeconomic regime, alongside relatively high rates, may mean investors need to demand greater compensation for taking on equity risk; they can meet this higher performance bar by getting precise about targeted opportunities. The AI...

2023-11-18 18:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...